Alpha Tau Medical Completes Patient Enrollment in Pancreatic Cancer Study

08:29 AM EDT, 08/31/2026 (MT Newswires) -- Alpha Tau Medical (DRTS) said Monday it has completed patient enrollment in a study evaluating intratumoral Alpha DaRT combined with first-line chemotherapy in newly diagnosed, inoperable locally advanced or metastatic pancreatic adenocarcinoma. The company said enrollment was increased to 48 patients from 12 originally and now includes those at different disease stages and receiving either of the two main first-line chemotherapy regimens. Initial data from the study is expected in early 2027, the company said.